Valaciclovir
- Generic Name
- Valaciclovir
- Brand Names
- Valtrex
- Drug Type
- Small Molecule
- Chemical Formula
- C13H20N6O4
- CAS Number
- 124832-26-4
- Unique Ingredient Identifier
- MZ1IW7Q79D
- Background
Valaciclovir (valacyclovir), also known as Valtrex, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 and marketed by GlaxoSmithKline . Valacyclovir is the L-valine ester of aciclovir. It is a member of the purine (guanine) nucleoside analog drug class ...
- Indication
Valacyclovir is a nucleoside analog DNA polymerase inhibitor indicated for :
Adults
• Cold Sores (Herpes Labialis)
• Genital Herpes
• Treatment of genital herpes lesions in immunocompetent patients (initial or recurrent episode)
• Suppression of genital herpes lesions in immunocompetent or HIV-infected patients
• Reduction of viral transmission
...
- Associated Conditions
- Chickenpox, Genital Herpes, Genital herpes, initial episode, Herpes Labialis, Herpes Zoster, Recurrent Genital Herpes (RGH)
- Associated Therapies
- Suppression of Recurrent Genital Herpes (RGH)
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 137
- Registration Number
- NCT01972035
- Locations
- 🇺🇸
University of MN, Minneapolis, Minnesota, United States
Phase III Study of ASP2151 in Herpes Zoster Patients
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Maruho Co., Ltd.
- Target Recruit Count
- 751
- Registration Number
- NCT01959841
Palatability Testing of a New Paediatric Formulation of Valacyclovir
- Conditions
- Interventions
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT01682109
- Locations
- 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- AiCuris Anti-infective Cures AG
- Target Recruit Count
- 91
- Registration Number
- NCT01658826
- Locations
- 🇺🇸
University of Texas Health Science Centre, Center for Clincial Studies, Houston, Texas, United States
🇺🇸University of Washington, Virology Research Clinic, Seattle, Washington, United States
🇺🇸Indiana University School of Medicine, IU Infectious Diseases Research, Indianapolis, Indiana, United States
CMV Modulation of the Immune System in ANCA-associated Vasculitis
- First Posted Date
- 2012-07-04
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Professor Lorraine Harper
- Target Recruit Count
- 38
- Registration Number
- NCT01633476
- Locations
- 🇬🇧
Wellcome Trust Clinical Research Facility, Birmingham, United Kingdom
Herpes Simplex Type 1 Suppression in Hepatitis C
- First Posted Date
- 2012-04-19
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 19
- Registration Number
- NCT01580995
- Locations
- 🇺🇸
G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS, Jackson, Mississippi, United States
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 31
- Registration Number
- NCT01453075
- Locations
- 🇺🇸
G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS, Jackson, Mississippi, United States
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 379
- Registration Number
- NCT01390857
To Rescue Cognition With Valaciclovir
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 24
- Registration Number
- NCT01364792
- Locations
- 🇳🇱
University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
- First Posted Date
- 2011-05-03
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT01346475
- Locations
- 🇺🇸
University of Washington Virology Research Clinic, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.